California, USA-based Sangamo Therapeutics (Nasdaq: SGMO) has announced the appointment of Jason Fontenot as senior vice president, cell therapy.
In his role, he will oversee Sangamo's growing engineered cell therapy portfolio, including a proprietary immunology pipeline based on chimeric antigen receptor regulatory T cells (CAR-Tregs), a partnership with France’s Sanofi (Euronext: SAN) focused on ex vivo genome-editing programs in hemoglobinopathies, and a partnership with Kite, a Gilead Sciences (Nasdaq: GILD) company, to develop allogeneic CAR-T cell therapies in oncology.
Prior to Sangamo, he served as chief scientific officer at Immusoft. Before Immusoft, he served as head of exploratory research at Juno Therapeutics.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze